164 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod http://www.zacks.com/stock/news/432688/pharma-stock-roundup-pfe-to-buy-arry-rhhby-mrk-azn-drugs-get-regulatory-nod?cid=CS-ZC-FT-432688 Jun 21, 2019 - Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs http://www.zacks.com/stock/news/432004/gilead-gild-teams-up-with-nurix-for-cancer-and-other-drugs?cid=CS-ZC-FT-432004 Jun 20, 2019 - Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
NVS or NVO: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/431571/nvs-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-431571 Jun 19, 2019 - NVS vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients http://www.zacks.com/stock/news/431041/novo-nordisks-victoza-gets-fda-nod-for-pediatric-patients?cid=CS-ZC-FT-431041 Jun 18, 2019 - Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod http://www.zacks.com/stock/news/429560/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod?cid=CS-ZC-FT-429560 Jun 14, 2019 - Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
NVO: Barclays ups to Equal Weight http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190611075113 Jun 11, 2019 - Barclays issues rating change for NVO
BMY or NVO: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/421291/bmy-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-421291 May 29, 2019 - BMY vs. NVO: Which Stock Is the Better Value Option?
GILD, NVO, ZYNE and NOG among notable after hour movers https://seekingalpha.com/news/3465165-gild-nvo-zyne-nog-among-notable-hour-movers?source=feed_news_all May 17, 2019 - Top Gainers: GILD +3.1%. NOG +3.2%. NBRV +2.7%. GOL +2.3%. NIO +1%.Top Losers: LTM -4.7%. SIGA -1.9%. NKTR -1.8%. NVO -1.7%. ZYNE -1.7%.
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug http://www.zacks.com/stock/news/412433/pharma-stock-roundup-agn-nvo-report-q1-earnings-nvs-to-buy-takedas-eye-drug?cid=CS-ZC-FT-412433 May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Novo Nordisk Trots Along Waiting for Its Next-Generation Oral Drug https://www.fool.com/investing/2019/05/09/novo-nordisk-trots-along-waiting-for-its-next-gene.aspx?source=iedfolrf0000001 May 09, 2019 - Oral semaglutide is on its way.

Pages: 123456...17

Page 1>